Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMaravai Lifesciences Holdings Inc

Maravai Lifesciences Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.15 USD 0.63 ( 8.38%)
Last update at 2026-11-09T15:47:00Z
VOLUME
419893
Market Cap
2548.06M

Momentum Score

…

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.50
Low
8.15
High
52 Week Price Range
2.54
Low
9.42
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Maravai Lifesciences supplies specialized reagents and platform technologies used by biopharma and diagnostics firms for mRNA, gene editing, viral vector production and molecular testing. Long-term growth may be supported by wider adoption of mRNA therapeutics, expansion of cell and gene therapies, and rising diagnostic demand, giving exposure to recurring consumables revenue.
Key risks include dependence on a limited number of large customers, revenue cyclicality tied to development and commercial timing, competitive and pricing pressures, and regulatory or supply-chain disruptions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.52
Dividend Yield
-
Revenue TTM
208.78M
Revenue Per Share
1.43
Gross Profit TTM
74.55M
Debt / Equity
0.17
ROE
-33.05%
Net Debt
-181.31M
ROCE
-28.66%
Diluted EPS TTM
-0.55

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -234.97M -261.48M 617.74M 551.47M 530.76M
Minority interest 99.99M 114.78M -34.47M -270.46M -287.21M
Net income -130.77M -144.85M -119.03M 490.66M 469.25M
Selling general administrative 145.12M 161.77M 150.12M 129.26M 100.06M
Gross profit 33.39M 108.31M 140.20M 714.04M 658.68M
Reconciled depreciation 60.47M 56.87M 45.83M 38.10M 24.75M
Ebit -207.98M -213.78M 663.63M 574.22M 554.64M
Ebitda -147.11M -156.92M 712.41M 568.40M 543.67M
Depreciation and amortization 60.87M 56.87M 48.78M -5.82M -10.97M
Non operating income net other - - - - 0.28M
Operating income -6.74M -235.62M -31.65M 574.22M 554.64M
Other operating expenses 192.48M 494.80M 320.59M 316.58M 255.84M
Interest expense 26.99M 47.70M 45.89M 20.41M 30.26M
Tax provision -4.21M -1.86M -1.61M 60.81M 61.52M
Interest income 11.44M 27.40M 22.61M 2.34M -
Net interest income -15.56M -20.30M -18.07M -18.08M -30.26M
Income tax expense -4.21M -1.86M 756.11M 60.81M 61.52M
Total revenue 185.74M 259.19M 288.94M 883.00M 799.24M
Total operating expenses 40.13M 343.93M 171.85M 147.63M 115.28M
Cost of revenue 152.35M 150.88M 148.74M 168.96M 140.56M
Total other income expense net -228.24M -25.86M 649.38M -22.74M -23.88M
Net income from continuing ops -230.76M -259.62M 59.04M 490.66M 469.25M
Net income applicable to common shares - - - 220.21M 182.04M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 770.58M 1008.24M 1487.45M 2282.32M 1918.28M
Intangible assets 151.54M 194.96M 220.99M 216.66M 117.57M
Other current assets 13.37M 18.14M 17.83M 25.80M 19.70M
Total liab 397.87M 431.04M 697.57M 1377.07M 1372.91M
Total stockholder equity 212.38M 325.29M 416.75M 545.22M 315.50M
Deferred long term liab - - - 2.20M 2.70M
Other current liab 14.99M 35.87M 60.53M 89.36M 65.69M
Common stock 2.56M 2.53M 2.51M 2.55M 2.55M
Capital stock 2.56M 2.53M 2.51M 2.55M 2.55M
Retained earnings 10.12M 140.89M 285.74M 404.77M 184.56M
Other liab - - - 693.38M 713.64M
Good will 129.43M 159.88M 326.03M 283.67M 152.77M
Other assets - - - 806.13M 812.47M
Cash 216.89M 322.40M 574.96M 632.14M 551.27M
Total current liabilities 44.92M 56.97M 87.47M 110.14M 93.78M
Current deferred revenue - 3.29M 3.36M 3.09M 10.21M
Net debt -181.31M 54.29M 36.01M -46.88M -16.96M
Short term debt 5.44M 6.23M 12.85M 11.71M 9.72M
Short long term debt 5.44M 5.44M 5.44M 5.44M 6.00M
Short long term debt total 35.58M 376.69M 610.97M 585.26M 534.31M
Other stockholder equity 199.18M 181.87M 128.50M 137.90M 128.39M
Property plant equipment - - - 116.59M 46.33M
Total current assets 296.25M 429.15M 699.91M 847.90M 740.04M
Net tangible assets - - - 44.89M 315.50M
Net receivables 25.50M 38.52M 55.72M 146.81M 117.51M
Long term debt 286.33M 290.49M 518.71M 522.00M 524.59M
Inventory 40.49M 50.08M 51.40M 43.15M 51.56M
Accounts payable 2.91M 11.96M 10.73M 5.99M 8.15M
Noncontrolling interest in consolidated entity - - - - 229.86M
Accumulated other comprehensive income 0.52M - - - -
Common stock total equity - - - - 2.55M
Retained earnings total equity - - - - 184.56M
Non currrent assets other 192.14M 7.24M 9.32M 51.69M 53.45M
Non current assets total 474.33M 579.10M 787.54M 1434.41M 1178.24M
Capital lease obligations 72.94M 80.76M 86.82M 57.83M 3.72M
Long term debt total - - - - 524.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -24.32M -127.93M -267.61M 105.66M
Change to liabilities - - - -8.70M -7.30M
Total cashflows from investing activities -31.41M -24.32M -122.31M -267.61M 105.66M
Net borrowings -5.44M -234.07M -5.77M -5.44M -6.00M
Total cash from financing activities -16.50M -235.71M -61.09M -187.50M -159.05M
Change to operating activities - - - -23.57M -17.49M
Net income -130.77M -259.62M -119.03M 490.66M 469.25M
Change in cash -105.51M -252.56M -57.18M 80.87M 315.09M
Begin period cash flow 322.40M 574.96M 632.14M 551.27M 236.18M
End period cash flow 216.89M 322.40M 574.96M 632.14M 551.27M
Total cash from operating activities -57.57M 7.46M 126.22M 535.98M 368.57M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 60.47M 56.87M 48.78M 38.10M 24.75M
Other cashflows from investing activities -31.41M 5.34M 12.87M -12.17M 120.50M
Dividends paid - - - - 153.45M
Change to inventory 8.00M 0.38M 0.65M 9.46M -21.57M
Change to account receivables 12.82M 14.36M 84.39M -22.27M -70.39M
Sale purchase of stock - -2.08M -0.02M 0.00M 1.71M
Other cashflows from financing activities -11.06M 0.44M -55.30M -173.60M -153.05M
Change to netincome - - - 319.96M 45.83M
Capital expenditures 13.15M 29.66M 65.55M 17.09M 14.85M
Change receivables - - - - -70.39M
Cash flows other operating - - - - -68.26M
Cash and cash equivalents changes - - - - 315.18M
Change in working capital -7.98M -12.61M 97.84M -45.08M -176.63M
Stock based compensation 30.17M 49.41M 34.59M 18.67M 10.46M
Other non cash items 20.73M 171.10M -690.90M -8.70M -6.16M
Free cash flow -70.72M -22.19M 60.67M 518.89M 353.72M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MRVI
Maravai Lifesciences Holdings Inc		 0.63
8.38%		 8.15 - 370.37 12.20 4.87 5.28 1.77
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Maravai Lifesciences Holdings Inc

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

10770 Wateridge Circle, San Diego, CA, United States, 92121

858 546 0004

https://www.maravai.com

415

Name Title Year Born
Mr. Carl W. Hull Co-Founder and Exec. Chairman & Interim CEO 1959
Mr. Kevin M. Herde Exec. VP & CFO 1972
Mr. Kurt Oreshack Exec. VP, Gen. Counsel & Sec. 1981
Ms. Christine Dolan Chief Operating Officer of Biologics Safety Testing 1968
Mr. Brian Neel Chief Operating Officer of Nucleic Acid Production 1976
Dr. Peter Michael Leddy Ph.D. Exec. VP & Chief Admin. Officer 1963
Ms. Debra Hart Sr. Director of Investor Relations NA
Ms. Doreen Pippen VP of Marketing NA
Mr. Carl W. Hull Co-Founder & Executive Chairman 1959
Mr. William E. Martin III Chief Executive Officer 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…